In Dermatology, assessment of people of color remains underrepresented in RCTs (<10%) and guidelines. Acne affects around 9% of the population worldwide and negatively affects quality of life and self-esteem with anxiety, suicidal ideation and physical scarring. Main lesions associate comedons, inflammatory papules and pustules which grading of severity allows decision-making, e.g., topicals in mild acne and isotretinoin in severe acne. In darker skin type patients, i.e., Fitzpatrick phototypes IV-VI, acne-related pigmentation (ARP) occurs in 65% of cases which reflects either per- or post-inflammatory hyperpigmentation. Whatever is the mechanism, ARP (number, size, importance of dyschromia) impacts the quality of life in such patients. In moderate acne, treatment is based on oral antibiotics for 3 months, i.e., doxycycline or lymecycline, with topical treatment like tretinoin targeting comedons (and potentially ARP). However, oral antibiotics first-line were developed in white skin patients only and never showed its efficacy in ARP. Moreover, doxycycline could be associated with new-onset hyperpigmentation in acne patients. Isotretinoin -acting on the sebaceous gland and therefore the most effective drug in acne- is only prescribed after failure of antibiotics according to the guidelines.The main objective: To assess the superiority at M6 of a treatment of moderate facial acne in skin of color patients with oral isotretinoin in first line compared to the current standard of care on the severity of ARP.Multicenter randomized controlled trial - open study. The number of subjects required for the trial = 420

Start Date01 Mar 2025

Sponsor / Collaborator

Centre Hospitalier Universitaire de Nice

NCT06698263

/ Not yet recruitingPhase 4IIT

13-cis Retinoic Acid (Isotretinoin) and Sperm Production

This study aims to evaluate the effectiveness of weekly administration of isotretinoin (40 mg) in increasing sperm production in men with oligozoospermia, a condition characterized by a low sperm count. Participants will be randomized into two groups: one receiving isotretinoin and the other a placebo. The primary outcome will be the change in sperm production over 20 weeks of treatment.

Start Date01 Mar 2025

Sponsor / Collaborator

Les Hopitaux Universitaires de Strasbourg

NCT06225570

/ RecruitingEarly Phase 1

Randomized Controlled Trial of Weekly Oral Isotretinoin vs. Oral Tetracyclines for the Treatment of Moderate Acne Vulgaris

In the effort to find better treatments for Moderate Acne, which often relies on long-term antibiotic use, researchers are exploring alternative options. While Isotretinoin, a Vitamin A derivative, is highly effective for severe acne, its side effects limit its use for milder cases. A recent study from our institution investigated a new approach: weekly Isotretinoin dosing. The results were promising, with acne improvement and no major side effects. This suggests that weekly Isotretinoin could be a successful alternative for moderate acne in both males and females. To validate these findings, investigators propose a randomized controlled trial comparing weekly Isotretinoin to daily Doxycycline over four months. This study could confirm the safety and effectiveness of weekly Isotretinoin, as well as shed light on patient satisfaction, and long-term results compared to standard antibiotics. This research may offer a breakthrough in treating moderate acne while addressing concerns about antibiotic overuse.

Start Date01 Feb 2025

Sponsor / Collaborator

Medical University of South Carolina

100 Clinical Results associated with Isotretinoin

100 Translational Medicine associated with Isotretinoin

100 Patents (Medical) associated with Isotretinoin

7,080

Literatures (Medical) associated with Isotretinoin

01 Mar 2025·Contemporary Clinical Trials

Evaluation of the safety and efficacy of isotretinoin in treatment of COVID-19 : A randomized controlled clinical trial

Article

Author: Abdelfatah, Wagdy ; El-Ghaiesh, Sabah H ; Elgarhy, Lamia H ; Hamed, Eman

The pandemic of SARS-CoV2 is not only limited to the health issues and fatalities encountered in a worldwide overwhelming burden but also the social, economic, and well-being devastation. Many trials were done to find a safe and reliable therapy for COVID-19. Isotretinoin was reported as a possible therapy for COVID-19 through the mining of post-transcriptomic and genomic datasets, which revealed isotretinoin as a potent down-regulator of the ACE2 protein the crucial gateway of SARS-CoV2 to hijack host cells. A total of 106 patients with mild to moderate COVID-19 were recruited. Patients were randomized into two groups and treated with the Standard Care (STD) protocol of the Ministry of Health, Egypt, or the STD in combination with isotretinoin (0.5 mg/kg/day) for 5 days. The study involved 66 (63 %) females and 39 (37 %) males, median age 42 years (interquartile 32-55.5 y). The main findings revealed a significant reduction in the time to improvement in the isotretinoin-treated (6.6 ± 2 d) compared to the STD-treated patients (10.4 ± 3.3). Survival analysis (HR: 4.1, 95 % CI: 2.5-6.6) in comparison to the STD-treated patients. The main adverse event reported during the therapeutic duration was the dryness of the skin, which was of acceptable tolerability through skin care instructions to the patients. The data presented herein highlights the efficacy of isotretinoin in the management of mild to moderate COVID-19 patients with a significant reduction of the time to recovery. The adverse events reported were tolerable and did not outweigh the therapeutic benefits.

01 Mar 2025·Journal of the American Academy of Dermatology

The impact of the COVID-19 pandemic and the iPLEDGE risk evaluation and mitigation strategies update on isotretinoin prescription delays and interruptions: An interrupted time series analysis

Article

Author: Beagles, Emma ; Shih, Allen F ; Chung, Hye Jin

01 Mar 2025·International Journal of Dermatology

A comparative exploration of immunohistochemical markers in patients with papulopustular rosacea undergoing treatment with oral isotretinoin versus doxycycline

Article

Author: Rocha, Marco Alexandre ; Enokihara, Milvia Maria Simões e Silva ; Costa, Caroline Sousa ; Picosse, Fabíola ; Bagatin, Ediléia ; Sanudo, Adriana

AbstractBackgroundRosacea is a chronic inflammatory disease, and doxycycline is a widely recommended treatment for it due to its anti‐inflammatory action. Oral isotretinoin reduces sebaceous gland activity and modulates toll‐like receptors, reducing inflammation. Our aim was to investigate the effect of these two drugs on the expression of cutaneous immunohistochemical biomarkers related to etiopathogenic factors involved in rosacea.MethodsWe conducted a randomized, comparative, and evaluator‐blinded trial, including 40 participants with moderate and severe papulopustular and ocular rosacea. Participants were treated with doxycycline (DOXY) 100 mg or isotretinoin (ISO) 0.3 mg/kg daily. Immunohistochemistry at baseline and after 4 months was used to demonstrate the expression of the biomarker on the affected skin.ResultsThe following changes were detected: a reduction in the vessel count after using VEGF with DOXY (P = 0.010); a decrease in VEGF intensity with ISO (P < 0.001) and DOXY (P = 0.020); a reduction of nitric oxide synthase enzyme with both drugs in the inflammatory infiltrate (ISO P < 0.001; DOXY P = 0.003); however, only with ISO was there a significant (P = 0.030) decrease at the level of the sebaceous glands, indicating a reduction of nitric oxide synthesis; a reduction of TRPV‐1 expression at the level of the sebaceous glands was observed only with DOXY (P = 0.041); a decrease of cathelicidin LL37 expression, a key antimicrobial peptide in the etiopathogenesis of rosacea, was noted with both drugs, although at the level of sebaceous glands, only with DOXY (P = 0.007).ConclusionsOral isotretinoin and doxycycline have modified the expression of cutaneous biomarkers related to rosacea etiopathogenesis, demonstrating their role in controlling inflammatory and vascular processes.

News (Medical) associated with Isotretinoin

07 Mar 2025

·www.prnewswire.com

TRANSFORM YOUR SKIN HEALTH: DIET AND LIFESTYLE TAKE CENTER STAGE AT 2025 AAD ANNUAL MEETING

ORLANDO, Fla., March 7, 2025 /PRNewswire/ -- The 2025 American Academy of Dermatology Annual Meeting will take place March 7-11 in Orlando. The meeting will feature nearly 300 educational sessions with more than 1,700 speakers discussing the latest research on skin, hair, and nails, including topics on how diet and lifestyle can transform skin health, eczema management, and insights into aging skin. A New Era in Skin Health: GLP-1 Medications Your skin is often a window to your overall health, including underlying inflammatory and metabolic conditions. New treatments, like GLP-1 medications commonly used for weight loss, can help manage obesity, reduce inflammation, and improve skin conditions, highlighting how board-certified dermatologists are advancing personalized care. Inflammation and Skin Conditions Are Linked: Obesity often causes inflammation that can worsen or trigger skin conditions like psoriasis, eczema, and hidradenitis suppurativa, a chronic disease that causes painful lumps to form under the skin. GLP-1 Medications and Your Skin: While originally developed to treat diabetes and, more recently, promote weight loss, GLP-1 medications can reduce inflammation caused by obesity and improve certain skin conditions. A New Era of Dermatology: Treating conditions like obesity can bring about a healthier 'you' and help skin treatments work better, leading to more complete care. Lindsey Bordone, MD, FAAD, an assistant professor of dermatology at Columbia University Department of Dermatology, can discuss the connection between obesity and skin health, and how addressing your overall health can benefit your skin and well-being. The Role of Diet in Managing Eczema Many people believe that food is the root cause of atopic dermatitis, commonly known as eczema, which can result in dry, itchy skin. However, the relationship between diet and this common skin condition is more complex than it seems. New research is shedding light on how diet influences eczema – which affects nearly one in ten Americans – and empowers patients to make more informed choices. Cutting Foods Isn't a Cure-All: For most patients, simply eliminating certain foods doesn't significantly improve eczema symptoms, despite common misconceptions. The Role of a Healthy Diet: Emphasizing overall healthy eating and avoiding allergens can still play an important role in managing eczema. Early Allergen Introduction: Introducing allergenic foods early in life may help build tolerance, offering a powerful shift in how people manage their eczema. Peter A. Lio, MD, FAAD, a clinical assistant professor of dermatology at Northwestern Medicine in Chicago, can provide evidence-based strategies for managing eczema through diet and lifestyle. How Diet Can Enhance the Effectiveness of Skin Treatments The foods you eat play a vital role in how well medications work for skin conditions and can even help to minimize possible side effects. By making thoughtful dietary choices, you can support your skin health, maximize the effectiveness of treatments for skin disease, and improve your overall health. Optimize Treatment with Nutrition: The Mediterranean diet, which encourages people to eat plant-based foods, and omega-3 fats, can help make biologic treatments for psoriasis more effective, while also reducing heart disease risks associated with this common skin condition. Support Immunotherapy with Fiber: For advanced melanoma, the deadliest form of skin cancer, a diet rich in fiber from fruits, vegetables, and whole grains enhances the effectiveness of immunotherapy, a cancer treatment that uses the patient's own immune system to fight the disease. At the same time, patients should avoid probiotic supplements, which can make treatments less effective. Complement Therapy with Supplements: For those who suffer from acne, omega-3 supplements improve the absorption of isotretinoin, a common acne medication, and minimize its side effects. Steven Daveluy, MD, FAAD, an associate professor of dermatology at Wayne State University in Dearborn, Michigan, details how your diet can work alongside your treatment plan for healthier skin and a healthier you. Understanding Itch: A Window into Aging Skin Itch is the most common symptom for which patients over 50 visit a dermatologist. Importantly, recent scientific breakthroughs and treatment innovations are revolutionizing dermatologists' understanding and management of this condition. More than a symptom, itch offers valuable insights into how the immune system, nervous system, and skin barrier – the outermost layer of skin that serves as a protective shield for the body – change as we age. Increasingly More Common and Severe: Itch becomes more common and severe with age, significantly impacting quality of life, including sleep, daily activities, and our ability to care for others. Complicated Causes in Older Adults: Diagnosing the cause of itch in older adults is harder because visual signs and lab clues are less definitive. This can result in undertreatment. Evolving Treatments: While there are no FDA-approved medications specifically for itch, dermatologists have a variety of treatments at hand to address its effects, including moisturizers as well as topical ointments, phototherapy, biologics – which target diseases throughout your body and neurologic treatments like nerve creams and oral medications. Daniel C. Butler, MD, FAAD, an assistant dean and an associate professor of dermatology at University of Arizona College of Medicine in Tucson, can discuss the types of personalized treatment options dermatologists recommend for patients who struggle with persistent itch. If you have questions about a skin, hair, or nail condition, consult a board-certified dermatologist to ensure you receive trusted, expert guidance tailored to your needs. About the AAD Headquartered in Rosemont, Ill., the American Academy of Dermatology, founded in 1938, is the largest, most influential and most representative of all dermatologic associations. With a membership of more than 21,000 physicians worldwide, the AAD is committed to advancing the diagnosis and medical, surgical, and cosmetic treatment of the skin, hair, and nails; advocating high standards in clinical practice, education and research in dermatology; and supporting and enhancing patient care because skin, hair, and nail conditions can have a serious impact on your health and well-being. For more information, contact the AAD at (888) 462-DERM (3376) or aad.org. Follow @AADskin on Facebook, Pinterest, and YouTube, and @AADskin1 on Instagram. SOURCE American Academy of Dermatology WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

07 Jan 2025

·www.prnewswire.com

Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma

Back to media releases Next media release LONDON, Jan. 7, 2025 /PRNewswire/ -- Norgine today announced that it completed its marketing authorisation application filing to European Medicines Agency (EMA) for eflornithine in high-risk neuroblastoma (HRNB). This follows the submissions in April 2024, via Project Orbis, in Australia, Switzerland and the United Kingdom. This milestone further supports Norgine's efforts to give patients access to eflornithine and bring a further treatment option in the field of paediatric oncology. Norgine and USWM, LLC (dba US WorldMeds), a Kentucky-based specialty pharmaceutical company, have an exclusive licensing agreement by which Norgine will register and commercialise eflornithine, also referred to as DFMO, in Europe, Australia and New Zealand. On 13 December 2023, the US Food and Drug Administration (FDA) approved eflornithine as the first oral maintenance therapy for HRNB, indicated to reduce the risk of relapse in adult and paediatric patients who have received certain prior therapies.[1] The approval decision was based on findings from a trial comparing outcomes from patients treated with eflornithine in Study 3b (NCT02395666)[2],[4] to control patients derived from Study ANBL0032 (NCT00026312; clinical-trial-derived external control arm)[3],[4]. The study with eflornithine treated patients showed improved event-free survival and overall survival when compared to outcomes for patients with HRNB treated with the standard of care (SoC).[1] Dr David Gillen, Chief Medical Officer at Norgine, added, "This submission via the EU Centralised Procedure represents another important step in the regulatory process for eflornithine and further emphasises Norgine's passion and commitment in attempting to secure additional treatment options for patients living with HRNB, a condition with a high level of unmet medical need." Janneke van der Kamp, CEO of Norgine added "Submitting this marketing authorisation to the EMA marks a pivotal step for patients facing this challenging cancer. We are committed to advancing innovative therapies that address the unmet needs of young patients and their families, and this milestone brings us closer to offering hope where it's most needed". Follow @norgine Notes to Editors: HRNB background Children diagnosed with HRNB undergo an intense SoC regimen that still leaves them vulnerable to relapse and death, a risk that is highest for the first two years after completing treatment.[5] Approximately 30% of patients who attain remission following upfront therapy will relapse, and once relapsed, mortality significantly increases with a post-relapse 4-year overall survival of under 10%.[5], [6] Therefore, avoiding relapse is key to long-term survival, yet outside of the United States there are no approved therapies for sustaining remission following SoC treatment. The data demonstrate that using eflornithine after completion of upfront SoC treatment, as post-maintenance therapy extends remission and reduces risk of relapse in patients with HRNB. About Norgine Norgine is a uniquely positioned, specialty pharmaceutical and consumer healthcare company, with over €500 million of annual revenues and a 120-year track record of bringing life-changing products to patients and consumers across our core markets of Western Europe, Australia and New Zealand. Our integrated approach – strong commercial capabilities, deep medical, regulatory and clinical expertise, in-house manufacturing, robust supply networks, and best in class enabling functions – ensures that we can deliver high-quality, transformative medicines quickly and effectively to over 25 million patients annually. Today's Norgine is a nimble, innovative, and high-performing company that has been transformed by a relentless focus on operational excellence. This focus will enable us to secure the legacy of more than a century of innovation and doing the right thing by our patients, as we push the boundaries and take strides into new therapeutic areas. NORGINE and the sail logo are trademarks of the Norgine group of companies. References FDA approves eflornithine for adult and pediatric patients with high-risk neuroblastoma. FDA. News release. 13 December 2023. Available from: FDA approves eflornithine for adult and pediatric patients with high-risk neuroblastoma | FDA Clinical Trial NCT02395666; Preventative trial of difluoromethylornithine (DFMO) in high risk patients with neuroblastoma that is in remission. Available from: Study Details | Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission | ClinicalTrials.gov. Clinical Trial NCT00026312; Isotretinoin with or without dinutuximab,[1] aldesleukin, and sargramostim following stem cell transplant in treating patients with neuroblastoma. Available from: Study Details | Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma | ClinicalTrials.gov Oesterheld J, Ferguson W, Kraveka JM, Bergendahl G, Clinch T, Lorenzi E et al. Eflornithine as Postimmunotherapy Maintenance in High-Risk Neuroblastoma: Externally Controlled, Propensity Score-Matched Survival Outcome Comparisons. 2024; 42 (1): 90-102. Basta NO, Halliday GC, Makin G, Birch J, Feltbower R, Bown N, et al. Factors associated with recurrence and survival length following relapse in patients with neuroblastoma. Br J Cancer. 2016;115:1048-57. London WB, Bagatell R, Weigel BJ, Fox E, Guo D, Van Ryn C, et al. Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials. Cancer. 2017;123:4914-23.[2] Job code: UK-ONC-NP-2400019 Logo - WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

License out/inDrug Approval

12 Nov 2024

·www.prnewswire.com

Expert Study Reveals Groundbreaking Results in Mild to Severe Acne Treatment On Skin Types I to VI with Aerolase Neo Elite® Laser

TARRYTOWN, N.Y., Nov. 12, 2024 /PRNewswire/ -- A pivotal study led by renowned U.S. dermatologist Dr. Nazanin Saedi showcases the remarkable efficacy of the Aerolase Neo Elite® 650-microsecond 1064nm Nd:YAG laser in treating mild, moderate, and severe acne vulgaris. Now published as a peer-reviewed article in the Journal of Drugs in Dermatology, the study highlights the transformative results achieved with Neo Elite®, setting a new benchmark for acne treatment. Dr. Saedi, a board-certified dermatologist and Associate Clinical Professor at Thomas Jefferson University, explains, "This laser treatment offers faster and more effective results than traditional methods. Patients prize the immediate improvement and the pain-free experience, which translates to their fuller adherence to a treatment plan – even when teenage patients get distracted by their multiple life activities." Overcoming the Challenges of Acne—the World's Most Pervasive Skin Concern Traditional acne treatments often fall short of delivering effective, timely results. Retinoids like isotretinoin and antibiotics can lead to significant side effects, while medications and older device-based approaches tend to have slow onsets of action and extended treatment timelines. Legacy devices struggle with poor patient compliance because of tolerability issues —further exacerbating the challenges of managing acne. The Neo Elite® was specifically designed to address these issues with its innovative energy delivery system and unique pulse parameters, offering a more effective and patient-friendly solution. Key Clinical Findings: Significant Acne Reduction: Dr. Saedi's evaluation revealed an 84% reduction in acne lesions by the end of the 2-3-month treatment course, with sustained results rising to 87% reduction 90 days post-treatment. These mark the highest and fastest clearances in the clinical literature. High Patient Satisfaction: Neo Elite® has garnered a 90% satisfaction rate, highlighting its effectiveness and patient comfort. Broad Applicability and Safety: Clinically proven effective and safe for all ages and skin types, including darker and tanned skin, Neo Elite® is ideal for a diverse patient base. Eliminates patient risk of side effects from systemic acne medication Revolutionary Mechanism of Action Aerolase Neo Elite® employs a 650-microsecond pulse duration to deliver precise energy that targets acne through multiple, synergistic mechanisms: Sebum Production Reduction: Neo Elite® normalizes sebum levels, creating a less acne-prone environment. Inflammation Mitigation: Laser energy coagulates inflammatory processes, calming active acne and promoting healing. Bacterial Elimination: The heat from the laser effectively neutralizes C. acnes bacteria, a primary acne trigger. Resolution of Acne Aftermath: Clearance of physical sequelae of acne including post-inflammatory hyperpigmentation, erythema, and acne scarring. A Prime Healthcare Provider Growth Engine With approximately 50 million pediatric and adult Americans suffering from acne, Neo Elite® offers a powerful, patient-driven solution that empowers medical and aesthetic providers to exceed patient expectations, expand their client base, and boost practice revenue. About Aerolase Aerolase is pioneering the future of skin wellness with breakthrough laser technology designed for everyone, everywhere. By combining science-backed efficacy and precision with universal accessibility, Aerolase empowers healthcare providers to deliver safe, effective treatments for all skin types and concerns. With a commitment to inclusivity, innovation, and trust, Aerolase is setting new standards in skincare, delivering advanced, life-changing treatments for all. Contact: Gary Giblen at [email protected] SOURCE Aerolase WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical Result

100 Deals associated with Isotretinoin

External Link

KEGG	Wiki	ATC	Drug Bank
D00348	Isotretinoin	D10BA01 D10AD04	DB00982

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Acne Vulgaris	Canada	Sun Pharmaceutical Industries Ltd.	22 Jun 2023
Acneiform Eruptions	United States	Sun Pharmaceutical Industries, Inc.	25 May 2012
Cystic acne	Australia	Roche Products Pty Ltd.	05 Dec 1994

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Autosomal recessive ichthyosis	Phase 3	Canada	-	21 Jun 2022
Ichthyosis, X-Linked	Phase 3	Germany	-	21 Jun 2022
Ichthyosis, X-Linked	Phase 3	Italy	-	21 Jun 2022
Ichthyosis, X-Linked	Phase 3	United States	-	21 Jun 2022
Ichthyosis, X-Linked	Phase 3	Canada	-	21 Jun 2022
Ichthyosis, X-Linked	Phase 3	France	-	21 Jun 2022
Congenital Ichthyosiform Erythroderma	Phase 3	-	Timber Pharmaceuticals LLCStartup	-
Acne Vulgaris	Phase 1	Canada	Cipher Pharmaceuticals, Inc.	01 Sep 2009
Acne Vulgaris	Phase 1	United States	Cipher Pharmaceuticals, Inc.	01 Sep 2009

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03076021 (CTgov)	Phase 4	Drug Metabolism, Poor, CYP2D6-Related	33	isotretinoin (Pre-isotretinoin)	miiwpdvhen(wvsbtitmtd) = qqrssghlld fnmrjemvby (qcrtddbjhu, swcyauiypo - dgtgbevxtv) View more	-	28 Jan 2025
NCT03076021 (CTgov)	Phase 4	Drug Metabolism, Poor, CYP2D6-Related	33	Isotretinoin (With Isotretinoin)	miiwpdvhen(wvsbtitmtd) = uvrcfnqrfm fnmrjemvby (qcrtddbjhu, lvohzaydwx - fjjvelfbgf) View more	-	28 Jan 2025
NCT05373901 (CTgov)	Phase 1	High Risk Neuroblastoma	8	Dinutuximab Beta+13-cis-Retinoic Acid	wmqrievldd(mupfrxwccu) = mbkqijigxx ztdpffblad (cpfvosnaga, vubbjqhdgc - pccxymepba) View more	-	04 Oct 2024
NCT04385277 (ANBL19P1, CTgov)	Phase 2	Ganglioneuroblastoma	41	FDG-Positron Emission Tomography+Iobenguane I-123+Dinutuximab+Temozolomide+Isotretinoin+Sargramostim+Irinotecan	(mxhsyiixtl) = mhjduaabaa vmffgakdbb (tmabrpghcb, fbpvibhsjj - rtlljhenlz) View more	-	14 Aug 2024
EADV2023	Not Applicable	-	-	Isotretinoin	jfzbzjwjdx(vqimsoncfg): HR = 0.82 (95% CI, 0.77 - 0.87), P-Value = <0.001 View more	Positive	11 Oct 2023
EADV2023	Not Applicable	-	-	Oral antibiotics		Positive	11 Oct 2023
EADV2023	Not Applicable	Irritable Bowel Syndrome \| Inflammatory Bowel Diseases	-	Isotretinoin	wxaaykveav(pzkorjyhpr) = yufxoxfkcs pvgohxkrsp (gdlbvghddq, 2.5 - 7.7)	Positive	11 Oct 2023
EADV2023	Not Applicable	Acne Vulgaris	1,191	Surgical extraction + Isotretinoin	gkglrfkjdx(vhddxpglad) = mlcreqxisi xlejwxtvsz (whelpctqcj ) View more	Positive	11 Oct 2023
THU376 (ENDO2023)	Not Applicable	Diabetes Mellitus, Type 2	-	Isotretinoin	jjiiwpfaqa(ygcrpzowok) = presented with hyperglycemia, acidosis, hypertriglyceridemia, elevated anion gap, low bicarbonate, and elevated ketones jxquhkkxod (fyeqktyvyp ) View more	Positive	05 Oct 2023
THU376 (ENDO2023)	Not Applicable	Diabetes Mellitus, Type 2	-	Basal-bolus insulin		Positive	05 Oct 2023
WCD2023	Not Applicable	Acne Vulgaris	30	Isotretinoin + SOD	dqcksagjmo(krhzqeazyp) = dcevbnftcc gpfduofdct (vgjymdyxgj )	Positive	03 Jul 2023
WCD2023	Not Applicable	Pustular psoriasis	-	Isotretinoin	(bmnczdcznx) = oyitlaxcnf qujluefxhc (xmdltxrsvl )	-	03 Jul 2023
EADV2023	Not Applicable	Acne Vulgaris	-	Isotretinoin	lxjbaaoqyq(xmfwpxgwlr) = wefhksxbwa nygaucsdsj (erdqbazywj ) View more	-	18 May 2023

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis